| Autor: |
Astradsson T; Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden., Sellberg F; Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden., Ehrsson YT; Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden., Sandström K; Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden., Laurell G; Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden. |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of molecular sciences [Int J Mol Sci] 2022 Jun 04; Vol. 23 (11). Date of Electronic Publication: 2022 Jun 04. |
| DOI: |
10.3390/ijms23116304 |
| Abstrakt: |
In this real-world study, the aims were to prospectively evaluate the expression of inflammatory proteins in serum collected from head and neck cancer patients before and after treatment, and to assess whether there were differences in expression associated with treatment modalities. The mixed study cohort consisted of 180 patients with head and neck cancer. The most common tumor sites were the oropharynx ( n = 81), the oral cavity ( n = 53), and the larynx ( n = 22). Blood tests for proteomics analysis were carried out before treatment, 7 weeks after the start of treatment, and 3 and 12 months after the termination of treatment. Sera were analyzed for 83 proteins using an immuno-oncology biomarker panel (Olink, Uppsala, Sweden). Patients were divided into four treatment groups: surgery alone (Surg group, n = 24), radiotherapy with or without surgery (RT group, n = 94), radiotherapy with concomitant cisplatin (CRT group, n = 47), and radiotherapy with concomitant targeted therapy (RT Cetux group, n = 15). For the overall cohort, the expression levels of 15 of the 83 proteins changed significantly between the pretreatment sample and the sample taken 7 weeks after the start of treatment. At 7 weeks after the start of treatment, 13 proteins showed lower expression in the CRT group compared to the RT group. The majority of the inflammatory proteins had returned to their pretreatment levels after 12 months. It was clearly demonstrated that cisplatin-based chemoradiation has immunological effects in patients with head and neck cancer. This analysis draws attention to several inflammatory proteins that are of interest for further studies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
